Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hologic ( (HOLX) ) has shared an announcement.
On April 6, 2026, Hologic announced that long-time Chairman, President and CEO Steve MacMillan, who joined the company in 2013 and became chairman in 2015, will retire immediately after the closing of its go-private acquisition by Blackstone and TPG. Under MacMillan’s more than 12-year tenure, Hologic delivered a 65% increase in revenue, a 184% rise in non-GAAP earnings per share, a 241% gain in its share price, and expanded its workforce by over 1,500 employees.
The company also disclosed on April 6, 2026 that it had received all regulatory approvals needed to complete the merger, which is expected to close on or about April 7, 2026, with a new CEO to be named at that time. The leadership transition comes as Hologic shifts from a public to a private ownership structure, marking a significant strategic milestone that could reshape its capital structure, governance, and long-term growth trajectory under Blackstone and TPG’s stewardship.
The most recent analyst rating on (HOLX) stock is a Hold with a $81.00 price target. To see the full list of analyst forecasts on Hologic stock, see the HOLX Stock Forecast page.
Spark’s Take on HOLX Stock
According to Spark, TipRanks’ AI Analyst, HOLX is a Neutral.
The score is driven primarily by strong cash flow generation and a stable balance sheet, which offset the sharp TTM revenue decline and margin compression. Technical indicators are neutral-to-soft with limited trend strength, while valuation appears relatively expensive at ~31x earnings without dividend yield support. Corporate events are mixed: shareholder approval supports deal progress, but litigation and product-related headwinds add risk.
To see Spark’s full report on HOLX stock, click here.
More about Hologic
Hologic, Inc. is an innovative medical technology company focused primarily on improving women’s health and well-being through early detection and treatment. The company develops products and solutions that target key areas of women’s health, positioning it as a significant player in the broader medical technology and diagnostics space.
Average Trading Volume: 2,809,582
Technical Sentiment Signal: Buy
Current Market Cap: $16.89B
For an in-depth examination of HOLX stock, go to TipRanks’ Overview page.